Compare Norfolk Southern Corporation (NSC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Norfolk Southern Corporation trades at $326.37 (market cap $72.13B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Norfolk Southern Corporation is far larger — about 14.8× Travere Therapeutics Inc. Common Stock's market cap, and Norfolk Southern Corporation pays a 1.68% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 34 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NSC | TVTX | |
|---|---|---|
Market Cap | $72.13B | $4.88B |
Volume | 650,750 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $352.98 | $67.52 |
52-Week Low | $278.19 | $26.79 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $87.68B | $5.01B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $321.14, up 0.56% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (21.02% net margin). Recent news highlights momentum for the Union Pacific merger, while institutional buying and a $361.86 consensus price target suggest upside potential.
Outlook remains positive with merger progress and dividend stability, but risks include fuel cost pressures and regulatory hurdles. The current valuation (P/E 27.4) demands execution on freight share gains and merger benefits to justify further gains.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
